Himalaya Nutravedics IPO

UpcomingSMEPharmaceuticals
Price band
₹100 – ₹106
Lot size
1,200
1 lot = ₹1,27,200
Issue size
₹26.5 Cr
Open – close
22 Sept 2026
to 24 Sept 2026
Listing
29 Sept 2026

What the filing actually says

Our read of the offer document and the exchange data — not the issuer's summary of itself

We can't judge this issue yet. A verdict needs at least three independent dimensions — valuation, growth, profitability, balance sheet, issue structure, governance or demand — and this issue does not yet publish enough of them for a read that would mean anything. No offer document for this issue has been published yet. A confident score from two fields would be worse than this notice.

Dates

The issuer's tentative timetable — a date passing is not confirmation the step completed

  1. Opens
    22 Sept 2026
  2. Closes
    24 Sept 2026
  3. Allotment
    25 Sept 2026
  4. Listing
    29 Sept 2026

The offering

Terms, structure and who is selling

Terms
Price band₹100 – ₹106
Face value₹10
Lot size1,200shares
Minimum application₹1,27,200at cut-off
Total issue size₹26.5 Cr
Listing atSME platform
Company & valuation
ISININE1OTR01013
RegistrarKFin Technologies Ltd

What happened to comparable issues

The last 8 issues to list with a recorded opening price, most comparable first

Median listing gain
+11.5%
Listed up
6 of 8
Best
+90.0%
Millworks Technologies
Worst
-0.7%
Mopshop Distribution
Shanti Inorganicssame segment
142.2× sub+90.0%
1.6× sub-0.7%
1.6× sub+0.0%
149.1× sub+22.1%
1.5× sub+6.9%
Dhaval Packagingsame segment
50.0× sub+13.4%
Sotefin Bharatsame segment
4.0× sub+9.6%
219.5× sub+90.0%

Past issues are context, not a forecast — this issue is a different company at a different price. We show it because "how have issues like this one actually opened" is a question with a real answer, and grey-market premium is not that answer.

About Himalaya Nutravedics

Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. Its product portfolio includes classical Ayurvedic formulations based on recognised Ayurvedic texts, proprietary Ayurvedic formulations and nutraceutical supplements. The products are available in dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils. Its nutraceutical products include formulations using vitamins, minerals, herbal extracts, amino acids and other permitted ingredients. The company operates through both its own-brand and third-party manufacturing businesses. It commenced manufacturing operations in September 2022 from its facility in Cherlapally, Hyderabad, Telangana. The company has a stockist-driven distribution network across multiple states in India and an on-ground sales and marketing team of approximately 56 personnel, including regional managers and medical representatives. Use of proceeds: This is a fresh issue of shares. Therefore, the net proceeds from the fresh issue will go to the company. They will be utilised for the following purposes: Funding capital expenditure requirements — Rs 13.75 crore Investment in branding, digital marketing, and sales expansion — Rs 7.50 crore General corporate purposes.

Founded 2022MD Mr Rohit AsawaSector Pharmaceuticals

Offer documents

The primary sources everything above is drawn from

Common questions

What is the minimum investment in the Himalaya Nutravedics IPO?

One lot is 1,200 shares, so a retail application at the ₹106 cut-off price blocks ₹1,27,200. Retail applications are capped at ₹2,00,000; above that you bid in the HNI category, where allotment is proportionate rather than by lottery.

When is the Himalaya Nutravedics IPO allotment date?

Allotment is scheduled for 2026-09-25, with listing on 2026-09-29. These dates are the issuer's tentative timetable — a date passing is not confirmation that the step completed. Allotment status is published by the registrar, KFin Technologies Ltd.

Disclaimer. Figures are compiled from the issuer's offer document and exchange-published bidding data. Subscription changes until the issue closes, and the final basis of allotment is published by the registrar. Grey-market premium is unofficial and is not a forecast. Nothing here is investment advice or a recommendation — read the offer document and consult a SEBI-registered adviser before applying.